A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy
Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5 or 6) + paclitaxel 175 mg/m2 with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma.
A Phase 3 Randomized Double-blind Trial of Maintenance with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer.
A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with relapsed ovarian sex-cord stromal tumours.
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer):A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum.
A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.
Groningen International Study on Sentinel Lymph Nodes in Vulvar Cancer II – An observational study
A Randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer.
Phase III, multicenter, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.
Randomized Phase III trial of Paclitaxel-Carboplatin with or without concomittant and maintenance AMG386 as First-line therapy of Stage III-IV ovarian, fallopian tube and peritoneal carcinoma.
A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers.
Phase III Randomised Study of Bevacizumab plus Chemotherapy versus Chemotherapy alone in Patients with Platinum Resistant Ovariumcancer.
A Multicentre, Randomized, Double-Blind, Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination with Standard Treatment of Carboplatin and Paclitaxel Compared to Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer.
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Stealth Liposomal Doxorubicin vs Carboplatin/Paclitaxel in patients with ovarian cancer recurrence between six and twelve months after previous platinum based chemotherapy: phase III multicenter randomized study.